Sucralfate is the generic form of the brand-name drug, Carafate. It is a prescription medicine used to treat ulcers of the upper gastrointestinal tract, peptic ulcer disease, and to prevent reoccurrence of ulcers. Sucralfate is a hydroxy aluminum salt of sucrose octasulfate that functions as a local mucosal adherent. It forms a coating over ulcers by sticking to the affected area, which protects the area from acid and enzymes and helps ulcers to heal more quickly.
Sucralfate can also be used in treating ulcers and upper gastrointestinal disorders of dog, horse, and cat, which may arise due to drugs (particularly non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids), toxic chemical ingestion, liver disease, renal failure, carcinoma, stress (trauma, shock, sepsis, and burns), and inflammatory bowel disease.
Sucralfate Market Drivers
Increasing research and development activities for discovering new medicine using sucralfate is expected to propel growth of the sucralfate market. For instance, according to the American Broncho Esophagological Association report in April 2018, use of sucralfate along with honey aids in treatment of esophageal injury in infants and children. Esophageal injury in infants and children is associated with consumption of Button Batteries (BB), small disc-shaped batteries commonly found in toys. Use of sucralfate with honey can help in mitigation of the button batteries and allows symptomatic relief from esophageal injury.
Sucralfate Market Restraint
Drug shortages are projected to hinder growth of the sucralfate market. For instance, according to Drug Shortages Canada, report of September 2018, APO-SUCRALFATE - TAB 1G (APOTEX INC) that contained sucralfate was not available due to disruption in the manufacturing of the drug. The drug is used to treat peptic ulcer and gastro esophageal reflux disease (GERD).
Sucralfate Market – Regional Analysis
On the basis of region, the global sucralfate market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold dominant position in the sucralfate market, owing to increasing number of clinical studies. For instance, University of Texas is conducting a clinical phase II study on sucralfate to improve oral intake in children with infectious oral ulcers. The study is expected to be completed by June 2019.
By 2026, Asia Pacific is expected to witness significant growth in the global sucralfate market due to increasing prevalence of H. pylori associated peptic ulcer disease, gastric cancer, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.
Key players operating in the global sucralfate market include, SRL Pharma, Nitika Chemicals., Teva Pharmaceutical Industries Ltd., Lisapharma S.p.A, Aptalis Pharma US, Inc., Uniprix Group, Rx Outreach, Abcam Plc, and Quimica Alkano.
Sucralfate Market – Taxonomy